US approves 1st vaccine for RSV after decades of attempts This electron microscope image provided by the National Institutes of Health shows human respiratory syncytial virus (RSV) virions, colorized blue, and anti-RSV F protein/gold antibodies, colorized yellow, shedding from the surface of human...
The US Food and Drug Administration on Friday approved Moderna's respiratory syncytial virus (RSV) vaccine for older adults—marking the first time any mRNA shot has been authorized against a disease other than COVID-19.
4.Ferguson, M. et al., "Noninferior Immunogenicity and Consistent Safety of Respiratory Syncytial Virus Prefusion F Protein Vaccine in Adults 50-59 Years Compared to ≥60 Years of Age" inClinicalInfectious Diseases, 2024; 79(4): 1074 . doi.org/10.1093/cid/ciae364 This information is provide...
Vaccination with AREXVY may not result in protection of all vaccine recipients Please see fullPrescribing Information. About the NCT05590403 Trial NCT05590403 is a phase III, placebo-controlled, observer-blind, randomized, multi-country immunogenicity trial to evaluate the non...
"I want to remind everyone that we have one of the best vaccine safety systems in the world. We have the ability to rapidly acquire information, rapidly assess it, and act on it. We saw that during the COVID pandemic, that system is viable, and is in place," the CDC's Dr. José...
GSK plc today announced that the FDA has approved Arexvy (respiratory syncytial virus vaccine, adjuvanted) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older.
This is the first RSV vaccine for older adults to be approved anywhere in the world. Tony Wood, Chief Scientific Officer, GSK, said:“Today marks a turning point in our effort to reduce the significant burden of RSV. Arexvy is the first approved RSV ...
More information:Concerns over informed consent for pregnant women in Pfizer's RSV vaccine trial,The BMJ(2023).DOI: 10.1136/bmj.p2620
However, the health body noted that it was continuing to review the treatment and that more research was needed to determine its effectiveness over a full RSV season. A separate measure, a maternal RSV vaccine called abrysvo, is already available in the United States for those in their 32nd...
Concerns regarding the faulty immunization "hindered development of alternative RSV vaccines for many years," experts at the WHO asserted in a statement. Nevertheless, in recent years, increased understanding of the biology of RSV and associated technological advances have resulted in multiple vaccine ca...